US Patent

US9956184 — Use of cannabinoids in the treatment of epilepsy

Method of Use · Assigned to GW Pharma Ltd · Expires 2035-06-17 · 9y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects the use of cannabidiol (CBD) for reducing total convulsive seizure frequency in treatment-resistant epilepsy, including Dravet syndrome and other conditions.

USPTO Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of âtreatment-resistant epilepsyâ (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Drugs covered by this patent

Epidiolex (CANNABIDIOL) · Jazz Pharms Res

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2424`	—	Epidiolex

Patent Metadata

Patent number: US9956184
Jurisdiction: US
Classification: Method of Use
Expires: 2035-06-17
Drug substance claim: No
Drug product claim: No
Assignee: GW Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.